Form 4: Intra-Cellular Therapies Director Rory B. Riggs Acquires Additional Shares

Director Rory B. Riggs acquired 262 shares of Intra-Cellular Therapies, Inc. at a price of $68.49 on June 28, 2024, increasing his total holdings to 116,862 shares.

Summary

• On June 28, 2024, Rory B. Riggs, a director of Intra-Cellular Therapies, Inc. (ITCI), purchased 262 shares of common stock.
• The purchase price was $68.49 per share.
• Following the transaction, Riggs directly owns 116,862 shares of ITCI common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, it's a relatively small transaction and doesn't necessarily indicate a major shift in sentiment.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider trading activity. It is common for directors and officers of publicly traded companies to buy and sell shares of their company's stock. These transactions are closely monitored by regulators and investors to ensure compliance with insider trading laws and to gain insights into management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.

Key Dates